Transfusion and Haematology Today - Issue 2/2012

Comprehensive Reports, Original Papers, Case Reports

58
Significance of hepcidin level assessment in the diagnosis of selected types of anaemia in childhood

D. Pospíšilová, J. Houda, D. Holub, B. Ludíková, R. Mojzíková, P. Pospíšilová, Z. Židová, K. Kapraľová, M. Horváthová, M. Hajdůch, P. Džubák

66
Early molecular response evaluation after 3 months of imatinib therapy in patients with chronic myeloid leukemia can contribute to estimation of prognosis – single centre experience

Š. Rožmanová, P. Rohoň, M. Divoká, J. Gazdová, M. Holzerová, I. Marešová, M. Jarošová, E. Faber, K. Indrák

72
Identification of Important Pathogenetic Mutations in Chronic Lymphocytic Leukemia Using „Next Generation Sequencing“

M. Mráz, M. Trbušek, D. Doležalová, J. Malčíková, J. Šupíková, K. Staňo-Kozubík, B. Kantorová, J. Mayer, Š. Pospíšilová

76
Current possibilities of laboratory diagnosis heparin-induced trombocytopenia

L. Slavík, G. Svobodová, J. Úlehlová, V. Krčová, A. Hluší, J. Procházková

81
n 18-year old Female with a History of Collapse – Case Report

J. Minařík, M. Skácelová, P. Horák, A. Smržová, L. Faltýnek, V. Ščudla


Selection of press reports and books

86
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

O. Hrodek

87
Safety of anticoagulants in children with arterial ischemic stroke

O. Hrodek

88
Morbidity and mortality in common variable immune deficiency over 4 decades

O. Hrodek

89
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

O. Hrodek

90
A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes

O. Hrodek

91
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

O. Hrodek

92
Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

O. Hrodek

93
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

O. Hrodek


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account